The relevant IP isn't the active pharmaceutical ingredient but the formulation and delivery method, and that appears to be out to 2035. http://www.accessdata.f

The relevant IP isn't the active pharmaceutical ingredient but the formulation and delivery method, and that appears to be out to 2035. http://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=204200 http://www.accessdata.fda.gov/scripts/cder/ob/results_produc... http://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Appl_type=N&Appl_No=204200&Product_No=001 http://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cf... I agree it's a good business plan as a solo participant in the market, but as a second or third entrant, probably less so-- depending on IP around the formulation and delivery method. With the number of company with discontinued products in the Orange book, i suspect there is some economic burden. that said there seems to be therapeptic equivalents available http://www.parsterileproducts.com/products/products/adrenalin-injection.php http://www.parsterileproducts.com/products/products/adrenali... so unless there is collusion, or a supply constraint, i'm not sure why the price will stand in the long term. (also is don't have expertise in this specific disease/drug so my comments could all be wrong). EDIT: i just realized i put int he IP links for PAR Pharma's product... i'm not sure what mylan's protection is but i have to get to work....)